Affinity Asset Advisors, LLC Curis Inc Transaction History

Affinity Asset Advisors, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$0.71 - $2.43 $6,852 - $23,451	-9,651 Reduced 2.76%	340,349 $335,000
Q1 2022 May 13, 2022	SELL	$2.31 - $5.13 $693,000 - $1.54 Million	-300,000 Reduced 46.15%	350,000 $833,000
Q4 2021 Feb 11, 2022	BUY	$4.45 - $8.09 $333,750 - $606,750	75,000 Added 13.04%	650,000 $3.09 Million
Q3 2021 Nov 12, 2021	SELL	$6.94 - $8.85 $520,500 - $663,750	-75,000 Reduced 11.54%	575,000 $4.5 Million
Q2 2021 Aug 13, 2021	SELL	$7.45 - $16.27 $2.61 Million - $5.69 Million	-350,000 Reduced 35.0%	650,000 $5.25 Million
Q1 2021 May 14, 2021	SELL	$8.78 - $12.8 $3.95 Million - $5.76 Million	-450,000 Reduced 31.03%	1,000,000 $11.3 Million
Q4 2020 Feb 12, 2021	BUY	$1.08 - $8.2 $1.57 Million - $11.9 Million	1,450,000 New	1,450,000 $11.9 Million

Ticker CRIS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 91,814,704
Market Cap $393M
Description
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myel...

Get notified when there are updates to the investment portfolio of Affinity Asset Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Affinity Asset Advisors, LLC with notifications on news.